CSMD1 and neoplasm: Another study discovered that miR-642b-3p acts as an oncomiR that promotes tumour progression in GC by repressing CSMD1 expression and inactivating the Smad signalling pathway, which could contribute to the development of potential therapies for GC treatment [75].